Sidvim LifeSciences Private Limited

  Contents Recent DMF filings                                                             General information                                                   Abbott and DexCom settle glucose monitor patent disputes Generic Pharmaceutical Manufacturer Secures Precedential Win at U.S. Federal Circuit Intellectual Property T 1238/22 (Pharmaceutical Compositions having Desirable Bioavailability / ALCON) 13-11-2024 Recent DMF filings   We follow DMF filings by Indian companies. In September 2024, 139 DMF filings were made, with Chinese companies contributing more than 75. In comparison, Indian companies lagged, filing 52 DMFs. MSN topped the list am...

  Report  Semaglutide and the Way Forward  Price Erosion, impact of GLP-1 agonist  Table of Contents Executive Summary 3 PART I 5 Various antidiabetic molecules are available, affecting different organs with their MOA. 5 Weight-loss 5 What is so special about semaglutide? 5 Different Semaglutide Brands 5 Efficacy: 6 Clinician’s perspective: 6 Our view: 7 When could patients avail of low-cost injectable semaglutide? 7 Patent and Regulatory Scenario: 7 LoE dates for injectable dosage forms: 8 Our view: 8 Price erosion: 8 US-Market 8 Europe-Markets 9 India 9 What is it for Semaglutide? 9 Our view 10 How safe is Semaglutide today? 10 Our view: 10 Price erosion calculations for Semaglutide : 10 Methodology followed 10 Case 1: 50% erosion, the situation would be as follows: 11 Case 2: 70% erosion, the situation would be as follows: 11 Our view: 11 PART II 11 The potential impact of generic Semaglutide launch on other GL...